Future studies involving larger cohorts are required to validate the GFAP and NT-proBNP combined algorithm; however, our study validates the diagnostic utility of blood-based biomarkers in the differentiation of IS and HS in the hyperacute phase of stroke. This evidence concerns the gene GFAP and stroke disorder.